NDASUBCUTANEOUSINJECTABLE
Approved
Apr 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
BYETTA (exenatide) by AstraZeneca is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for glp-1 receptor agonist [epc]. First approved in 2005.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BYETTA (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved in 2005 for the treatment of type 2 diabetes mellitus. It works by mimicking GLP-1, a hormone that stimulates insulin secretion in response to elevated blood glucose levels. Administered via subcutaneous injection, BYETTA is positioned as a second-line or add-on therapy for patients inadequately controlled on metformin or sulfonylureas. The drug has demonstrated benefits in glycemic control and weight reduction, though it is now approaching loss of exclusivity.
$0.0BPart D
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
GLP-1 Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus
Started Jan 2026
9 enrolled
T2DM
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
Started Sep 2024
24,000 enrolled
Pancreatic Cancer
Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function
Started May 2022
24 enrolled
Type2Diabetes
Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
Started Jun 2020
0Type 2 Diabetes
SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease
Started Mar 2020
99 enrolled
Early Parkinson's Disease
Worked on BYETTA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.